Effects of Prior Alkylating Therapies on Preinfusion Patient Characteristics and Starting Material for CAR T Cell Product Manufacturing in Late-Line Multiple Myeloma
Sign Up to like & getrecommendations! Published in 2020 at "Blood"
DOI: 10.1182/blood-2020-134369
Abstract: Introduction: Identifying prior therapy exposures that affect the patient or their peripheral blood mononuclear cell (PBMC) material is one strategy to optimize outcomes to CAR T cell therapy. Alkylating agents commonly used in multiple myeloma… read more here.
Keywords: company; current equity; traded company; publicly traded ... See more keywords
Idecabtagene Vicleucel (ide-cel, bb2121) Responses Are Characterized By Early and Temporally Consistent Activation and Expansion of CAR T Cells with a T Effector Phenotype
Sign Up to like & getrecommendations! Published in 2020 at "Blood"
DOI: 10.1182/blood-2020-134378
Abstract: Background: Patients (pts) with relapsed and refractory multiple myeloma (RRMM) experience unsatisfactory outcomes with established treatment modalities. In the pivotal phase 2 KarMMa study (NCT03361748), idecabtagene vicleucel (ide-cel, bb2121) demonstrated frequent, deep, and durable responses… read more here.
Keywords: company; current equity; traded company; publicly traded ... See more keywords
Targeting MYD88-Mutant DLBCL with IRAKIMiDs: A Comparison to IRAK4 Kinase Inhibition and Evaluation of Synergy with Rational Combinations
Sign Up to like & getrecommendations! Published in 2020 at "Blood"
DOI: 10.1182/blood-2020-135898
Abstract: Introduction: MYD88 mutations are found in 25% of DLBCL and are associated with an inferior survival. MYD88 is an adapter molecule, forming the core of the Myddosome complex. MYD88 mutations constitutively activate pathways such as… read more here.
Keywords: equity holder; current equity; therapeutics current; myd88 ... See more keywords
Uptake of Novel Therapies into First-Line Treatment for AML Patients - EU5 Perspective
Sign Up to like & getrecommendations! Published in 2020 at "Blood"
DOI: 10.1182/blood-2020-135921
Abstract: Introduction: Treatment options for acute myeloid leukaemia (AML) patients have increased in recent years as several novel targeted medications for AML patients have been introduced. The aim of this study was to identify the integration… read more here.
Keywords: aml patients; holder publicly; equity holder; current equity ... See more keywords
Effect of Food on MDM2 Inhibitor KRT-232 Pharmacokinetics and Macrophage Inhibitory Cytokine-1 (MIC-1) Response in Healthy Volunteers
Sign Up to like & getrecommendations! Published in 2020 at "Blood"
DOI: 10.1182/blood-2020-135985
Abstract: Background: KRT-232 is a potent, selective, orally available, small-molecule drug that binds to mouse double minute 2 homolog (MDM2) and inhibits its interactions with tumor suppressor protein p53. KRT-232 is under development for treatment of… read more here.
Keywords: company; current employment; current equity; krt 232 ... See more keywords
Population Pharmacokinetics and Exposure-Response Analyses for Glofitamab in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R NHL): Confirmation of Efficacy and CRS Mitigation in Patients with Step-up Dosing
Sign Up to like & getrecommendations! Published in 2020 at "Blood"
DOI: 10.1182/blood-2020-136311
Abstract: Introduction: Glofitamab (RG6026; RO7082859; CD20-TCB) is a novel '2:1' format T-cell-engaging bispecific antibody that has two CD20 and one CD3 binding domains, enabling increased tumor antigen avidity, rapid T-cell activation, and enhanced tumor cell killing… read more here.
Keywords: hoffmann roche; current employment; roche current; current equity ... See more keywords
Gene Therapy for Fanconi Anemia, Complementation Group a: Updated Results from Ongoing Global Clinical Studies of RP-L102
Sign Up to like & getrecommendations! Published in 2020 at "Blood"
DOI: 10.1182/blood-2020-137106
Abstract: Background: Fanconi anemia (FA) is a rare inherited disorder of defective cellular deoxyribonucleic acid (DNA) repair, associated with developmental abnormalities and characterized by progressive bone marrow failure (BMF) and a predisposition to hematologic malignancies and… read more here.
Keywords: current equity; rocket pharmaceuticals; company; pharmaceuticals inc ... See more keywords
Cael-101 Is Well-Tolerated in AL Amyloidosis Patients Receiving Concomitant Cyclophosphamide-Bortezomib-Dexamethasone (CyborD): A Phase 2 Dose-Finding Study (NCT04304144)
Sign Up to like & getrecommendations! Published in 2020 at "Blood"
DOI: 10.1182/blood-2020-139323
Abstract: Immunoglobulin light Chain (AL) amyloidosis is the most common form of systemic amyloidosis, accounting for approximately 70% of the diagnosed cases in developed countries. There are no approved treatments for AL amyloidosis, and currently autologous… read more here.
Keywords: cael 101; amyloidosis; caelum biosciences; equity holder ... See more keywords
Improving Physician-Patient Decision Making for Treatment of Chronic Lymphocytic Leukemia with BTK Inhibition
Sign Up to like & getrecommendations! Published in 2020 at "Blood"
DOI: 10.1182/blood-2020-140462
Abstract: Educational Need Advancements in evidence-based treatment strategies with approved BTK inhibitors ibrutinib and acalabrutinib are improving survival of patients with chronic lymphocytic leukemia (CLL). These advances create knowledge and practice gaps as new BTK inhibitors… read more here.
Keywords: consultancy research; consultancy; research funding; current equity ... See more keywords
In Vitro Characterization of FTX6058, a Novel Small Molecule Fetal Hemoglobin Inducer for Sickle Cell Disease
Sign Up to like & getrecommendations! Published in 2020 at "Blood"
DOI: 10.1182/blood-2020-141145
Abstract: Red blood cell disorders like Sickle Cell Disease (SCD) and β-thalassemias are caused by mutations within the gene for the hemoglobin β (HBβ) subunit. A fetal ortholog of HBβ, hemoglobin γ (HBγ) can prevent or… read more here.
Keywords: hemoglobin; ftx 6058; current equity; equity holder ... See more keywords
A Phase 1a/b Dose Escalation Study of the MYC Repressor Apto-253 in Patients with Relapsed or Refractory AML or High-Risk MDS
Sign Up to like & getrecommendations! Published in 2020 at "Blood"
DOI: 10.1182/blood-2020-141409
Abstract: INTRODUCTION: APTO-253 is the only known small molecule in clinical development to target a conserved G-quadruplex structure in the promoter of the MYC oncogene and interrupt MYC gene expression. In preclinical studies of acute myeloid… read more here.
Keywords: aptose biosciences; inc current; biosciences inc; current equity ... See more keywords